Inhaled budesonide for early treatment of COVID-19 - Authors' reply.

Ramakrishnan, Sanjay; Bafadhel, Mona

Ramakrishnan, Sanjay; Bafadhel, Mona.

Ramakrishnan S; Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK; National Institute for Health Research (NIHR), Oxford Biomedical Research Centre, Oxford, UK; School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
Bafadhel M; Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK; National Institute for Health Research (NIHR), Oxford Biomedical Research Centre, Oxford, UK. Electronic address: mona.bafadhel@ndm.ox.ac.uk.

Lancet Respir Med ; 9(7): e61, 2021 07.

Article in English | MEDLINE | ID: covidwho-1778525

Subject(s)

Anti-Asthmatic Agents; COVID-19; Budesonide; Formoterol Fumarate; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-Asthmatic Agents / COVID-19 Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article Affiliation country: S2213-2600(21)00212-5

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google